Literature DB >> 24351733

Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease.

Mirthe E van der Valk1, Marie-Josée J Mangen2, Max Leenders1, Gerard Dijkstra3, Ad A van Bodegraven4, Herma H Fidder1, Dirk J de Jong5, Marieke Pierik6, C Janneke van der Woude7, Mariëlle J L Romberg-Camps8, Cees H M Clemens9, Jeroen M Jansen10, Nofel Mahmmod11, Paul C van de Meeberg12, Andrea E van der Meulen-de Jong13, Cyriel Y Ponsioen14, Clemens J M Bolwerk15, J Reinoud Vermeijden16, Peter D Siersema1, Martijn G H van Oijen17, Bas Oldenburg18.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is associated with high costs to society. Few data on the impact of IBD on work disability and potential predictive factors are available. AIM: To assess the prevalence of and predictive factors for work disability in Crohn's disease (CD) and ulcerative colitis (UC).
METHODS: A web-based questionnaire was sent out in seven university hospitals and seven general hospitals in the Netherlands. Initially, 3050 adult IBD patients were included in this prospective, nationwide cohort study, whereof 2629 patients were within the working-age (18-64 years). We used the baseline questionnaire to assess the prevalence rates of work disability in CD and UC patients within working-age. Prevalence rates were compared with the Dutch background population using age- and sex-matched data obtained from Statistics Netherlands. Multivariable logistic regression analyses were performed to identify independent demographic- and disease-specific risk factors for work disability.
RESULTS: In CD, 18.3% of patients was fully disabled and 8.8% partially disabled, compared to 9.5% and 5.4% in UC patients (p<0.01), respectively. Compared to Dutch controls, the prevalence was significantly higher, especially in CD patients. Higher age, low education, depression, chronic back pain, joint manifestations and typical disease-related risk factors such as penetrating disease course and surgery in the past were all found to be associated with work disability.
CONCLUSION: We report high work disability rates in a large sample of IBD patients in the Netherlands. CD patients suffer more frequently from work disability than UC patients. A combination of demographic and disease-related factors is predictive of work disability.
Copyright © 2013 European Crohn's and Colitis Organisation. All rights reserved.

Entities:  

Keywords:  Crohn's disease; Risk factors; Ulcerative colitis; Work disability

Mesh:

Year:  2013        PMID: 24351733     DOI: 10.1016/j.crohns.2013.11.019

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  16 in total

1.  IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study.

Authors:  Alexis Ramos; Xavier Calvet; Beatriz Sicilia; Mercedes Vergara; Ariadna Figuerola; Jaume Motos; Adoración Sastre; Albert Villoria; Fernando Gomollón
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

2.  The socio-economic impact of work disability due to inflammatory bowel disease in Brazil.

Authors:  Renata de S B Fróes; Ana Teresa Pugas Carvalho; Antonio Jose de V Carneiro; Adriana Maria Hilu de Barros Moreira; Jessica P L Moreira; Ronir R Luiz; Heitor S de Souza
Journal:  Eur J Health Econ       Date:  2017-05-18

Review 3.  Impact of inflammatory bowel disease on disability.

Authors:  Katharina Büsch; Amnon Sonnenberg; Nick Bansback
Journal:  Curr Gastroenterol Rep       Date:  2014-10

Review 4.  The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.

Authors:  Christopher A Lamb; Aamir Saifuddin; Nick Powell; Florian Rieder
Journal:  Gastroenterology       Date:  2022-01-04       Impact factor: 22.682

Review 5.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

6.  Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Authors:  Michael D Mandel; Mandel D Michael; Anita Bálint; Barbara D Lovász; László Gulácsi; Bálint Strbák; Petra A Golovics; Klaudia Farkas; Zsuzsanna Kürti; Blanka K Szilágyi; Anna Mohás; Tamás Molnár; Péter L Lakatos
Journal:  Eur J Health Econ       Date:  2014-05-16

7.  Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.

Authors:  Niels Teich; Michael Bläker; Frank Holtkamp-Endemann; Eric Jörgensen; Andreas Stallmach; Susanne Hohenberger
Journal:  Inflamm Intest Dis       Date:  2020-12-18

8.  In-silico analysis of inflammatory bowel disease (IBD) GWAS loci to novel connections.

Authors:  Md Mesbah-Uddin; Ramu Elango; Babajan Banaganapalli; Noor Ahmad Shaik; Fahad A Al-Abbasi
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

9.  The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.

Authors:  Aaron Yarlas; Linnette Yen; Paul Hodgkins
Journal:  Qual Life Res       Date:  2014-09-06       Impact factor: 4.147

10.  Women's Earnings are more Affected by Inflammatory Bowel Disease than Men's: A Register-Based Swedish Cohort Study.

Authors:  Åsa H Everhov; Gustaf Bruze; Jonas Söderling; Johan Askling; Jonas Halfvarson; Karin Westberg; Petter Malmborg; Caroline Nordenvall; Jonas F Ludvigsson; Ola Olén
Journal:  J Crohns Colitis       Date:  2021-06-22       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.